MELBOURNE, March 31, 2013: Access to the IMAGINE Phase 2 clinical trial investor conference call hosted on Monday 31st March Australian EDT is available via Open Briefing.
FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: US-based equity research analyst George B. Zavoico, Managing Director of H.C. Wainwright & Co, has published a report on Prana Biotechnology's (ASX:PBT / NASDAQ:PRAN) Phase 2 trial of PBT2 in patients with Huntington's disease, Reach2HD.
FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: Prana Biotechnology (ASX:PBT / NASDAQ:PRAN) has prepared a presentation for investors regarding the results of its Phase 2 clinical trial of PBT2 in patients with Huntington's disease.
FEBRUARY 2014: MELBOURNE, Australia and NEW YORK, USA: Prana Biotechnology (ASX:PBT / NASDAQ:PRAN) has today announced the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.
FEBRUARY 2014: Prana Biotechnology will hold an investor conference call and webcast for professional investors on Wednesday 19th February at 9.30am Australian Eastern Daylight Savings Time (Tuesday 18th February US EST 5.30pm; US PST 2.30pm) to discuss the results of its Reach2HD Phase 2 clinical trial investigating PBT2 as a treatment for Huntington disease.
JANUARY 2014: Prana Biotechnology (ASX:PBT/ NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in neurodegenerative disease, is commencing a non-deal investor roadshow in the United States with Credit Suisse.
MELBOURNE, December 11, 2013: Prana Biotechnology (ASX:PBT; NASDAQ:PRAN), a developer of best-in-class treatments for neurodegenerative disease, today provided an update of its IMAGINE Alzheimer’s Disease (AD) Extension trial.
MELBOURNE, December 9, 2013: Prana Biotechnology (ASX:PBT; NASDAQ:PRAN), a developer of best-in-class treatments for neurodegenerative disease, today announced the completion of the treatment phase of its IMAGINE Alzheimer’s Disease (AD) clinical trial.
Prana Biotechnology (ASX:PBT/
NASDAQ:PRAN), a leading innovative drug developer targeting disease modification in
neurodegenerative disease, will present at The 2013 Therapeutic Area Partnerships (TAP)
meeting in Boston, USA.
Receive news from Alterity Therapeutics
